282 related articles for article (PubMed ID: 37108492)
1. Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated Review.
Wang CY; Wang CW; Chen CB; Chen WT; Chang YC; Hui RC; Chung WH
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108492
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis.
Ovejero-Benito MC; Muñoz-Aceituno E; Reolid A; Saiz-Rodríguez M; Abad-Santos F; Daudén E
Am J Clin Dermatol; 2018 Apr; 19(2):209-222. PubMed ID: 28921458
[TBL] [Abstract][Full Text] [Related]
3. Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine.
Berna-Rico E; Perez-Bootello J; Abbad-Jaime de Aragon C; Gonzalez-Cantero A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37372997
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics and the resulting impact on psoriasis therapies.
Foulkes AC; Warren RB
Dermatol Clin; 2015 Jan; 33(1):149-60. PubMed ID: 25412789
[TBL] [Abstract][Full Text] [Related]
5. Whole Exome Sequencing in Psoriasis Patients Contributes to Studies of Acitretin Treatment Difference.
Zhou X; He Y; Kuang Y; Li J; Zhang J; Chen M; Chen W; Su J; Zhao S; Liu P; Chen M; Shen M; Chen X; Zhu W; Chen X
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146080
[TBL] [Abstract][Full Text] [Related]
6. Retrospective pharmacogenetic study of psoriasis highlights the role of KLK7 in tumour necrosis factor signalling.
Zhang H; Patrick MT; Tejasvi T; Sarkar MK; Wasikowski R; Stuart PE; Li Q; Xing X; Voorhees JJ; Ward NL; He K; Zhou X; Gudjonsson JE; Nair RP; Elder JT; Tsoi LC
Br J Dermatol; 2023 Dec; 190(1):70-79. PubMed ID: 37672660
[TBL] [Abstract][Full Text] [Related]
7. The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis.
Ryan C; Menter A; Warren RB
Mol Diagn Ther; 2010 Apr; 14(2):81-93. PubMed ID: 20359251
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population.
Vasilopoulos Y; Manolika M; Zafiriou E; Sarafidou T; Bagiatis V; Krüger-Krasagaki S; Tosca A; Patsatsi A; Sotiriadis D; Mamuris Z; Roussaki-Schulze A
Mol Diagn Ther; 2012 Feb; 16(1):29-34. PubMed ID: 22111980
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis.
Indhumathi S; Rajappa M; Chandrashekar L; Ananthanarayanan PH; Thappa DM; Negi VS
Eur J Clin Pharmacol; 2017 Aug; 73(8):965-971. PubMed ID: 28444425
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of psoriasis.
O'Rielly DD; Rahman P
Pharmacogenomics; 2011 Jan; 12(1):87-101. PubMed ID: 21174624
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of topical and systemic treatment of psoriasis.
Prieto-Pérez R; Cabaleiro T; Daudén E; Ochoa D; Román M; Abad-Santos F
Pharmacogenomics; 2013 Oct; 14(13):1623-34. PubMed ID: 24088133
[TBL] [Abstract][Full Text] [Related]
12. How genetic variation affects patient response and outcome to therapy for psoriasis.
Woolf RT; Smith CH
Expert Rev Clin Immunol; 2010 Nov; 6(6):957-66. PubMed ID: 20979559
[TBL] [Abstract][Full Text] [Related]
13. Biologics combined with conventional systemic agents for the treatment of children with severe psoriasis. Real-life data from the BiPe cohorts and a practice survey among French and Italian pediatric dermatologists.
Mahé E; Beauchet A; Hadj-Rabia S; Mazereeuw-Hautier J; Mallet S; Phan A; Severino-Freire M; Boralevi F; Aubert H; Barthélémy H; Girard C; Martin L; Piram M; Barbarot S; Balguerie X; Zitouni J; Phan C; Di Lernia V;
Dermatol Ther; 2022 Nov; 35(11):e15828. PubMed ID: 36107157
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics and pharmacogenomics in psoriasis treatment: current challenges and future prospects.
Sutherland A; Power RJ; Rahman P; O'Rielly DD
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):923-35. PubMed ID: 27266955
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in GNMT and DNMT3b are associated with methotrexate treatment outcome in plaque psoriasis.
Grželj J; Mlinarič-Raščan I; Marko PB; Marovt M; Gmeiner T; Šmid A
Biomed Pharmacother; 2021 Jun; 138():111456. PubMed ID: 33714108
[TBL] [Abstract][Full Text] [Related]
16. Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis.
Loft ND; Skov L; Iversen L; Gniadecki R; Dam TN; Brandslund I; Hoffmann HJ; Andersen MR; Dessau RB; Bergmann AC; Andersen NM; Andersen PS; Bank S; Vogel U; Andersen V
Pharmacogenomics J; 2018 May; 18(3):494-500. PubMed ID: 28696418
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics: An Update on Biologics and Small-Molecule Drugs in the Treatment of Psoriasis.
Caputo V; Strafella C; Cosio T; Lanna C; Campione E; Novelli G; Giardina E; Cascella R
Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573380
[TBL] [Abstract][Full Text] [Related]
18.
Zhou X; He Y; Kuang Y; Chen W; Zhu W
Front Biosci (Landmark Ed); 2022 Sep; 27(9):266. PubMed ID: 36224009
[TBL] [Abstract][Full Text] [Related]
19. HLA-G 14-bp polymorphism: a possible marker of systemic treatment response in psoriasis vulgaris? Preliminary results of a retrospective study.
Borghi A; Rizzo R; Corazza M; Bertoldi AM; Bortolotti D; Sturabotti G; Virgili A; Di Luca D
Dermatol Ther; 2014; 27(5):284-9. PubMed ID: 24909182
[TBL] [Abstract][Full Text] [Related]
20. Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis.
Murdaca G; Negrini S; Magnani O; Penza E; Pellecchio M; Puppo F
Expert Opin Drug Saf; 2017 Oct; 16(10):1173-1179. PubMed ID: 28750567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
